TY - JOUR T1 - <sup>18</sup>F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 88 LP - 99 DO - 10.2967/jnumed.108.054205 VL - 50 IS - 1 AU - Simona Ben-Haim AU - Peter Ell Y1 - 2009/01/01 UR - http://jnm.snmjournals.org/content/50/1/88.abstract N2 - Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in the evaluation of a patient presenting with cancer. With 18F-FDG, PET/CT is rapidly becoming the key investigative tool for the staging and assessment of cancer recurrence. In the last 5 y, PET/CT has also gained widespread acceptance as a key tool used to demonstrate early response to intervention and therapy. In this setting, a major clinical need is being addressed with 18F-FDG PET/CT, because of its inherent ability to demonstrate (before other markers of response) if disease modification has occurred. This review presents available evidence to this effect. ER -